Literature DB >> 25710457

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Nils Winkelmann1, Matthew Rose-Zerilli2, Jade Forster2, Marina Parry2, Anton Parker3, Anne Gardiner4, Zadie Davies4, Andrew J Steele2, Helen Parker2, Nicholas C P Cross5, David G Oscier3, Jonathan C Strefford6.   

Abstract

Entities:  

Keywords:  early stage chronic lymphocytic leukemia; low frequency mutations; monoclonal B-cell lymphocytosis; treatment-free survival

Mesh：

Year:  2015        PMID： 25710457      PMCID： PMC4450638          DOI： 10.3324/haematol.2014.120238

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

Review 2.  The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications.

Authors:  Jonathan C Strefford
Journal:  Br J Haematol       Date:  2014-12-11       Impact factor: 6.998

3.  Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.

Authors:  Alejandra Martínez-Trillos; Magda Pinyol; Alba Navarro; Marta Aymerich; Pedro Jares; Manel Juan; María Rozman; Dolors Colomer; Julio Delgado; Eva Giné; Marcos González-Díaz; Jesús M Hernández-Rivas; Enrique Colado; Consolación Rayón; Angel R Payer; Maria José Terol; Blanca Navarro; Victor Quesada; Xosé S Puente; Ciril Rozman; Carlos López-Otín; Elías Campo; Armando López-Guillermo; Neus Villamor
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

4.  Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.

Authors:  J Ojha; C Secreto; K Rabe; J Ayres-Silva; R Tschumper; D V Dyke; S Slager; R Fonseca; T Shanafelt; N Kay; E Braggio
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

5.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.

Authors:  Andrew J Ramsay; Víctor Quesada; Miguel Foronda; Laura Conde; Alejandra Martínez-Trillos; Neus Villamor; David Rodríguez; Agnieszka Kwarciak; Cecilia Garabaya; Mercedes Gallardo; Mónica López-Guerra; Armando López-Guillermo; Xose S Puente; María A Blasco; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330

7.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Authors:  David G Oscier; Matthew J J Rose-Zerilli; Nils Winkelmann; David Gonzalez de Castro; Belen Gomez; Jade Forster; Helen Parker; Anton Parker; Anne Gardiner; Andrew Collins; Monica Else; Nicholas C P Cross; Daniel Catovsky; Jonathan C Strefford
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

8.  A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

Authors:  O G Best; A C Gardiner; Z A Davis; I Tracy; R E Ibbotson; A Majid; M J S Dyer; D G Oscier
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

9.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528
  9 in total
  10 in total

1.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

2.  A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Authors:  Iraia García-Santisteban; Igor Arregi; Marián Alonso-Mariño; María A Urbaneja; Juan J Garcia-Vallejo; Sonia Bañuelos; Jose A Rodríguez
Journal:  Cell Mol Life Sci       Date:  2016-06-16       Impact factor: 9.261

3.  Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.

Authors:  Geffen Kleinstern; Daniel R O'Brien; Xing Li; Shulan Tian; Brian F Kabat; Kari G Rabe; Aaron D Norman; Huihuang Yan; Celine M Vachon; Nicholas J Boddicker; Timothy G Call; Sameer A Parikh; Laura Bruins; Cecilia Bonolo de Campos; Jose F Leis; Tait D Shanafelt; Wei Ding; James R Cerhan; Neil E Kay; Susan L Slager; Esteban Braggio
Journal:  Am J Hematol       Date:  2020-05-07       Impact factor: 10.047

4.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

5.  POT1 mutations are frequent and associated with Ki-67 index in canine diffuse large B-cell lymphoma.

Authors:  Antonella Fanelli; Laura Marconato; Luca Licenziato; Lucia Minoli; Nicole Rouquet; Luca Aresu
Journal:  Front Vet Sci       Date:  2022-08-09

6.  Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Authors:  S Barrio; T D Shanafelt; J Ojha; K G Chaffee; C Secreto; K M Kortüm; S Pathangey; D L Van-Dyke; S L Slager; R Fonseca; N E Kay; E Braggio
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

7.  Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Authors:  Naomi Elster; Sinead Toomey; Yue Fan; Mattia Cremona; Clare Morgan; Karolina Weiner Gorzel; Una Bhreathnach; Malgorzata Milewska; Madeline Murphy; Stephen Madden; Jarushka Naidoo; Joanna Fay; Elaine Kay; Aoife Carr; Sean Kennedy; Simon Furney; Janusz Mezynski; Oscar Breathhnach; Patrick Morris; Liam Grogan; Arnold Hill; Susan Kennedy; John Crown; William Gallagher; Bryan Hennessy; Alex Eustace
Journal:  Ther Adv Med Oncol       Date:  2018-07-13       Impact factor: 8.168

Review 8.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

9.  Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.

Authors:  Timothy M Barrow; Sirintra Nakjang; Fadhel Lafta; Kateryna Bilotkach; Laura Woodhouse; Gesa Junge; Susan J Tudhope; Jonathan P Wallis; Helen Marr; Scott Marshall; Nick Bown; Elaine Willmore; Gordon Strathdee
Journal:  Br J Cancer       Date:  2020-10-21       Impact factor: 7.640

10.  Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.

Authors:  Marc Zapatka; Eugen Tausch; Selcen Öztürk; Deyan Yordanov Yosifov; Martina Seiffert; Thorsten Zenz; Christof Schneider; Johannes Blöhdorn; Hartmut Döhner; Daniel Mertens; Peter Lichter; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.